Search

A retrospective study published in JAMA Dermatology suggests that a longer course of intravenous (IV) ertapenem may be appropriate for patients with recalcitrant hidradenitis suppurativa (HS). The study found that patients who self-administered IV ertapenem for an average of 13 weeks experienced improvements in clinical and inflammatory markers, and expressed satisfaction with the treatment. The researchers recommend a course of 12 to 16 weeks of ertapenem as a new standard length of therapy for HS patients. However, an accompanying editorial raises concerns about the potential increase in antimicrobial resistance associated with prolonged use of ertapenem. [Extracted from the article]

A retrospective study published in JAMA Dermatology suggests that a longer course of intravenous (IV) ertapenem may be effective in treating recalcitrant hidradenitis suppurativa (HS). The study found that patients who self-administered IV ertapenem for an average of 13 weeks experienced improvements in clinical and inflammatory markers. The researchers recommend a course of 12 to 16 weeks of ertapenem as a new standard length of therapy for HS patients. However, an accompanying editorial raises concerns about the potential increase in antimicrobial resistance associated with prolonged use of broad-spectrum antibiotics like ertapenem. [Extracted from the article]